Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Horizontal rectus tenotomy in patients with congenital nystagmus (CN): results in ten adults

Go back to Resources

Horizontal rectus tenotomy in patients with congenital nystagmus (CN): results in ten adults

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Results from the Inaugural Year of the Collaborative Islet Transplant Registry (CITR)

Go back to Resources

Results from the Inaugural Year of the Collaborative Islet Transplant Registry (CITR)

Authors:

Location:

Go back to Resources

Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities & neuromuscular disease. 2004 Pediatric Academic Societies Meeting

Go back to Resources

Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities & neuromuscular disease. 2004 Pediatric Academic Societies Meeting

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities & neuromuscular disease

Go back to Resources

Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities & neuromuscular disease

Authors:

Location:

Go back to Resources

Priming with a candidate HIV-1 clade A DNA vaccine followed by boosting with an HIV-1 Clade A MVA vaccine in volunteers at low risk of HIV infection

Go back to Resources

Priming with a candidate HIV-1 clade A DNA vaccine followed by boosting with an HIV-1 Clade A MVA vaccine in volunteers at low risk of HIV infection

Authors:

Location:

Go back to Resources

Pretransplant recipient cytomegalovirus seropositivity and hemodialysis are associated with decreased renal allograft and patient survival

Go back to Resources

Pretransplant recipient cytomegalovirus seropositivity and hemodialysis are associated with decreased renal allograft and patient survival

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Predictors of length of stay for pediatric liver transplant recipients

Go back to Resources

Predictors of length of stay for pediatric liver transplant recipients

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Posttransplant survival in pediatric fulminant hepatic failure: the SPLIT experience

Go back to Resources

Posttransplant survival in pediatric fulminant hepatic failure: the SPLIT experience

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS

Go back to Resources

Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Phase II Trial of Celebrex in Photodynamic Therapy (C-PDT) for Neovascular Age-related Macular Degeneration (AMD): Rationale and Baseline Characteristics

Go back to Resources

Phase II Trial of Celebrex in Photodynamic Therapy (C-PDT) for Neovascular Age-related Macular Degeneration (AMD): Rationale and Baseline Characteristics

Authors:

Location:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 141
  • Page 142
  • Page 143
  • Page 144
  • Current page 145
  • Page 146
  • Page 147
  • Page 148
  • Page 149
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • ISO Certification